JP2013533228A5 - - Google Patents

Download PDF

Info

Publication number
JP2013533228A5
JP2013533228A5 JP2013513651A JP2013513651A JP2013533228A5 JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5 JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
solvate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013513651A
Other languages
English (en)
Japanese (ja)
Other versions
JP5791707B2 (ja
JP2013533228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/059300 external-priority patent/WO2011154359A1/de
Publication of JP2013533228A publication Critical patent/JP2013533228A/ja
Publication of JP2013533228A5 publication Critical patent/JP2013533228A5/ja
Application granted granted Critical
Publication of JP5791707B2 publication Critical patent/JP5791707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013513651A 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用 Active JP5791707B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10165550.4 2010-06-10
EP10165550 2010-06-10
EP11158464 2011-03-16
EP11158464.5 2011-03-16
PCT/EP2011/059300 WO2011154359A1 (de) 2010-06-10 2011-06-06 Neue auristatin-derivate und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013533228A JP2013533228A (ja) 2013-08-22
JP2013533228A5 true JP2013533228A5 (enExample) 2014-07-03
JP5791707B2 JP5791707B2 (ja) 2015-10-07

Family

ID=44275637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013513651A Active JP5791707B2 (ja) 2010-06-10 2011-06-06 新規アウリスタチン誘導体およびその使用

Country Status (7)

Country Link
US (1) US8722629B2 (enExample)
EP (1) EP2579887B1 (enExample)
JP (1) JP5791707B2 (enExample)
CN (1) CN103200950B (enExample)
CA (1) CA2801971C (enExample)
ES (1) ES2528956T3 (enExample)
WO (1) WO2011154359A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2813056C (en) 2010-09-29 2018-09-18 Bayer Intellectual Property Gmbh N-carboxyalkyl auristatins and the use thereof
CA2829736C (en) * 2011-03-16 2020-07-21 Seattle Genetics, Inc. N-carboxyalkylauristatins and use thereof
CN103826661B (zh) 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途
KR101733853B1 (ko) 2011-11-17 2017-05-08 화이자 인코포레이티드 세포독성 펩티드 및 그의 항체 약물 접합체
EP2790731A2 (de) * 2011-12-14 2014-10-22 Seattle Genetics, Inc. Fgfr-binder-wirkstoff konjugate und ihre verwendung
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
RU2714933C2 (ru) 2013-12-27 2020-02-21 Займворкс Инк. Конъюгаты var2csa-лекарственное средство
MX378281B (es) 2014-04-25 2025-03-10 Pf Medicament Conjugado farmaco-anticuerpo y su uso para el tratamiento contra el cancer.
HUE044862T2 (hu) 2014-04-25 2019-11-28 Pf Medicament IGF-1R ellenanyag-drog konjugátum és alkalmazása rák kezelésében
DK3194421T3 (da) 2014-09-17 2022-02-14 Zymeworks Inc Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN108690119B (zh) * 2018-06-04 2022-04-19 莎穆(上海)生物科技有限公司 一种伊文思蓝修饰的多肽类前药及其制备和应用
AU2022253902A1 (en) 2021-04-10 2023-11-02 Genmab A/S Folr1 binding agents, conjugates thereof and methods of using the same
JP7742892B2 (ja) 2021-04-23 2025-09-22 ジェンマブ エー/エス 抗cd70抗体、そのコンジュゲートおよびこれを使用する方法
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
US20250115680A1 (en) 2023-09-26 2025-04-10 Profoundbio Us Co. Ptk7 binding agents, conjugates thereof and methods of using the same
US20250296992A1 (en) 2024-01-10 2025-09-25 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
CA2315230C (en) * 1998-01-09 2004-06-29 Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University Anti-cryptococcal peptides
MXPA01011502A (es) 1999-05-14 2003-08-20 Boehringer Ingelheim Pharma Compuestos de tipo profarmaco anti-tumorigenos, activados por enzimas.
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
JP4200100B2 (ja) * 2001-11-07 2008-12-24 アジェンシス,インコーポレイテッド 癌の処置および検出において有用な161p2f10bと称される、核酸および対応タンパク質
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
AU2006269422B2 (en) * 2005-07-07 2012-12-06 Seagen Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the C-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
DK2502938T3 (en) 2006-10-27 2015-04-20 Genentech Inc Antibodies and immunoconjugates and uses thereof
WO2009117531A1 (en) 2008-03-18 2009-09-24 Seattle Genetics, Inc. Auristatin drug linker conjugates
CN103826661B (zh) * 2011-04-21 2019-03-05 西雅图基因公司 新的结合剂-药物缀合物(adc)及其用途

Similar Documents

Publication Publication Date Title
JP2013533228A5 (enExample)
US20210161844A1 (en) Compositions containing tucaresol or its analogs
JP2013540114A5 (enExample)
JP2020506951A5 (enExample)
KR20180084063A (ko) 아르기닌 활성 억제용 조성물 및 방법
JP2017525730A5 (enExample)
JP2018535967A5 (enExample)
JP2014510149A5 (enExample)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2012525393A5 (enExample)
JP2009536620A5 (enExample)
JP2010539110A5 (enExample)
JP2011509309A5 (enExample)
JP2020523388A5 (enExample)
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
RU2008119692A (ru) Новые 1-азабициклоалкилпроизводные для лечения психических растройств
EP3890749A1 (en) Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
EP4058427A1 (en) Tucaresol derivatives and uses thereof
JP2019535723A5 (enExample)
JP2013522368A5 (enExample)
US20230233557A1 (en) Formulations comprising heterocyclic protein kinase inhibitors
JPWO2023195529A5 (enExample)
JP2017525717A5 (enExample)
RU2001135802A (ru) Антагонисты рецептора брадикинина
JP2011518168A5 (enExample)